Archive: Company News

Company News: Micromet’s BiTE Antibody MT112/BAY 2010112 Demonstrates Potent Activity against Human Prostate Cancer Cells

Micromet, Inc. (NASDAQ: MITI) yesterday evening announced the presentation of pre-clinical data on its BiTE antibody MT112/BAY 2010112, discovered and developed in collaboration with Bayer HealthCare Pharmaceuticals, at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida.

The data (poster # 4561) demonstrate the potent activity of the BiTE antibody against human cancer cell lines and inhibition of tumor growth in animal models.  MT112/ BAY 2010112 directed human and non-human primate T cells against PSMA-positive human prostate cancer cells, resulting in highly efficient cancer cell destruction. In mice, daily doses of MT112/BAY 2010112 as low as 0.05 milligram/kilogram were sufficient to inhibit growth of tumors from human prostate cancer cells.

During the course of the meeting, the Company also presented preclinical data on MT110, its BiTE antibody targeting epithelial cell adhesion molecule (EpCAM).  Results reported (poster # 1790) provide further validation of EpCAM as a cancer stem cell target, and show utility of MT110 to eradicate cancer stem cells derived from breast and hepatocellular carcinoma.

Company News: bubbles & beyond launches printing roll cleansing agent line enpurex®

Next-generation, superior intelligent cleansing fluids reduce printing down time, get rid of dangerous substances

bubbles & beyond, a technology company focusing on customized intelligent fluids™, today announced the official launch of its enpurex® product line, a range of next-generation cleansing agents that mark the beginning of a new era in printing industry cleaning. The cleansers are water-based, non-flammable, free from aggressive chemicals, biodegradable, and also superior to existing products in terms of efficacy. enpurex® products are based on bubbles & beyond´s novel, proprietary intelligent fluids™ approach and offer significant process cost savings, excellent compatibility of materials, optimum efficacy and operating safety.

Company News: Anergis Closes CHF 18 Million Series A Financing Round to Develop its Innovative Allergy Vaccines and Expands its Board of Directors

Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors. Anergis SA is a clinical-stage biopharmaceutical company developing innovative immunotherapies against allergies. Its lead product, called “AllerT” and made of so-called Contiguous Overlapping Peptides (COPs), is designed to provide ultra-fast and safe desensitization to birch pollen allergy, a widely spread condition in developed countries.

The financing round was co-led by three major European funds with extensive biotech experience: Vinci Capital-Renaissance PME (Lausanne, Switzerland), BioMedInvest (managed by BioMedPartners AG, Basel, Switzerland) and Sunstone Capital (Copenhagen, Denmark). The syndicate was also joined by Esperante (Limhamn, Sweden), Initiative Capital Romandie (Lausanne, Switzerland) and by private investors. Up until now, Anergis has invested CHF 3 million in its innovative allergy vaccines. These funds were raised from private investors and from a grant by the Swiss Innovation Fund (CTI).

The newly joining investors also bring substantial pharmaceutical experience and know-how to Anergis: Patrick Scherrer (representing Vinci Capital-Renaissance PME), Markus Hosang (representing BioMedInvest) and Sten Verland (representing Sunstone Capital) have joined the Anergis Board of Directors. The Board will be chaired by André J. Mueller, a professional with unique executive and non-executive experience in biotech ventures, which he gained with Biogen and Actelion and as the Chairman of the Boards of Cerenis Therapeutics (Toulouse) and Addex Pharmaceuticals (Geneva).

Company News: bubbles & beyond closes second financing round

bubbles & beyond, a technology company focusing on customized intelligent fluids, has announced the successful closing of a second financing round. All existing investors – LBBW Venture Capital, S-Beteiligungen, Hightech-Gruenderfonds and KfW – participated in the round, which totals EUR 1.2m.

The new funds will be used to strengthen the international market presence of bubbles & beyond and to broaden its internal development capacities in order to meet the increasing demand for customized intelligent fluids™ in various industry sectors. This includes diversified commercialization opportunities in the printing industry, microelectronics, and facility cleaning sectors in Europe and Japan. bubbles & beyond already markets products for graffiti removal as well as cleaning and preservation of building structures on the market. A product portfolio of professional cleaning agents for print rolls will be launched soon. In addition, there is considerable market demand for bubbles & beyond´s intelligent fluids™ in functional cosmetics.

Read more

1 … 141 142 143 … 152